RxDoctor Payments Data

Erik Howell, MD

Interventional Cardiology · Livonia, MINPI 1134410970

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $643 of the $975 with a category attached, or 65.9%. 8 manufacturers reported payments, led by Edwards Lifesciences at 48.7% of the total. Reporting peaked in 2019 at $475 and has fallen 81.4% since, to $88 in 2024. That places this record below the midpoint for interventional cardiology clinicians in MI, where the typical reported total is $6,857.

$975in general payments, 2019–2025

Across 18 payments — averaging $54.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$475
  • Boston Scientific$162
  • Abiomed$148
  • Medtronic$114
  • Atricure, Inc.$24
  • Cardiovascular Systems Inc.$21
  • plus $32 from 2 others
$102,641in research payments, 2019–2025

Across 9 payments — averaging $11,405 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$85K
  • Pfizer$17K

What the payments were for

  • Travel & lodging$33334%
  • Food & beverage$64366%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$975 in reported general payments places this provider in the 10th percentile of 187 interventional cardiology providers in Michigan.

See all interventional cardiology providers in Michigan

Medicare billing

Part B allowed, 2024
$104,492
Medicare patients
574
Services billed
1,058

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban349$392,141
XareltoRivaroxaban52$70,004
Repatha SureclickEvolocumab22$33,714
Metoprolol Succinate614$11,666
Atorvastatin Calcium393$7,155
Rosuvastatin Calcium210$4,015
Diltiazem 24hr Er (Cd)Diltiazem Hcl101$2,652
ClopidogrelClopidogrel Bisulfate152$2,545
Losartan Potassium195$2,420
Lisinopril214$2,210
Amlodipine Besylate226$2,191
Spironolactone189$2,189
Bumetanide55$1,932
Ezetimibe75$1,812
Carvedilol96$1,380

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Livonia

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →